Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and Translational Science"
DOI: 10.1111/cts.13499
Abstract: JZP458 is a recombinant Erwinia chrysanthemi asparaginase for patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who have developed hypersensitivity to Escherichia coli–derived asparaginases. A population pharmacokinetic (PopPK) model was developed for intramuscular (i.m.) JZP458… read more here.
Keywords: recombinant erwinia; jzp458; patients acute; asparaginase ... See more keywords
Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016923
Abstract: AALL1931 (NCT04145531), a phase 2/3 study conducted in collaboration with the Children's Oncology Group, investigated the efficacy and safety of JZP458 (asparaginase erwinia chrysanthemi (recombinant)-rywn), a recombinant Erwinia asparaginase derived from a novel expression platform,… read more here.
Keywords: recombinant erwinia; jzp458; asparaginase; cohort ... See more keywords